[1]杨登科,靳风烁.分枝杆菌Ag85B/IL-2融合蛋白对小鼠膀胱癌抑癌效应的研究[J].第三军医大学学报,2007,29(18):1772-1775.
 YANG Deng-ke,JIN Feng-shuo.Anti-tumor effect of mycobacterium Ag85B/IL-2 fusion protein on syngeneic mice bearing bladder cancer[J].J Third Mil Med Univ,2007,29(18):1772-1775.
点击复制

分枝杆菌Ag85B/IL-2融合蛋白对小鼠膀胱癌抑癌效应的研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
29卷
期数:
2007年第18期
页码:
1772-1775
栏目:
论著
出版日期:
2007-09-30

文章信息/Info

Title:
Anti-tumor effect of mycobacterium Ag85B/IL-2 fusion protein on syngeneic mice bearing bladder cancer
作者:
杨登科靳风烁
第三军医大学大坪医院野战外科研究所泌尿外科
Author(s):
YANG  Deng-ke JIN Feng-shuo
Department of Urology, Research Institute of Field Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, China
关键词:
分枝杆菌Ag85BIL-2膀胱癌抑癌效应
Keywords:
mycobacterium Ag85B interleukin 2 bladder cancer anti-tumor effect
分类号:
R73-362;R730.23;R737.14
文献标志码:
A
摘要:
目的  探讨分枝杆菌Ag85B/IL-2融合蛋白对小鼠膀胱癌的抑癌效应。 方法  采用小鼠T739可移植性膀胱癌模型,共80只分为10组,于移植瘤处局部注射分枝杆菌Ag85B/IL-2融合蛋白,并用Ag85B蛋白、BCG、IL-2和生理盐水作对照,观察治疗后各组的肿瘤质量、体积和存活期。光镜和电镜下观察肿瘤的形态改变。 结果  分枝杆菌Ag85B/IL-2融合蛋白治疗组小鼠肿瘤瘤质量(2.49±0.60) g,非常显著低于Ag85B蛋白组、BCG组、IL-2组和生理盐水组(P<0.01);Ag85B/IL-2融合蛋白治疗组小鼠肿瘤瘤体积(3.01±0.95)cm3,显著低于Ag85B蛋白组、BCG组、IL-2组和生理盐水组(P<0.05,P<0.01);Ag85B/IL-2融合蛋白治疗组小鼠存活天数(35.50±2.60) d,显著长于Ag85B蛋白组,BCG组、IL-2组和生理盐水组(P<0.05,P<0.01);Ag85B/IL-2融合蛋白对小鼠的肿瘤质量抑制率为64.50%,肿瘤体积抑制率为62.24%,存活延率为48.66%。光镜下观察Ag85B/IL-2融合蛋白治疗组肿瘤细胞有明显的炎性细胞浸润、肿瘤细胞坏死、出血等改变;透射电镜下观察,可见细胞膜破裂,细胞器破坏,细胞质固缩,细胞核破坏,核染色质聚集,凋亡小体出现,巨噬细胞吞噬增多等现象。 结论  分枝杆菌Ag85B/IL-2融合蛋白对小鼠膀胱癌具有抑制作用,并能延长膀胱癌荷瘤鼠的生存期。
Abstract:
Objective    To study the anti-tumor effect of mycobacterium Ag85B/IL-2 fusion protein on syngenic mice bearing bladder cancer.     Methods    After being implanted BTT739 bladder transitional carcinoma cells from tumor bearing mice, 80 T739 mice were divided into Ag85B protein, BCG, IL-2 and normal saline groups (n=20). Mycobacterium Ag85B/IL-2 protein was locally injected to the mice at the site of implanting tumor in the trial group, and Ag85B protein, BCG, IL-2 and normal saline to the control group mice. The weight and volume of tumor and the survival period were recorded after treatment.     Results    The average weight of Ag85B/IL-2 fusion protein treatment group was significantly lower than those of Ag85B, BCG,IL-2 and normal saline group (P<0.01). The average volume of Ag85B/IL-2 fusion protein treatment group was significantly lower than those of Ag85B, BCG,IL-2 and normal saline group (P<0.05, P<0.01). The average survival period of Ag85B/IL-2 fusion protein treatment group was significantly longer than those of Ag85B, BCG,IL-2 and normal saline group (P<0.05, P<0.01). The tumor weight and volume inhibition rate of Ag85B/IL-2 fusion protein were 64.50% and 62.24%, respectively, and the survival period prolonging rate of Ag85B/IL-2 fusion protein was 48.66%. Under light microscope, the bladder tumor tissue treated by Ag85B/Il-2 presented obviously inflammatory cells infiltrating, neoplasm necrosis, hemorrhage. With transmission electron microscope, the bladder tumor cell membrane was un-integrated, organelles damaged, cytoplasm pycnosis, nucleus fragmentation, aggregation on chromatin, apoptosis body coming up, macrophage swollen and so on.     Conclusion    The results indicate that mycobacterium Ag85B/IL-2 protein has obvious anti-tumor effect in T739 mice bearing bladder cancer and can prolong its survival period.

参考文献/References:

杨登科,靳风烁.  分枝杆菌Ag85B/IL-2融合蛋白对小鼠膀胱癌抑癌效应的研究[J].第三军医大学学报,2007,29(18):1772-1775.

相似文献/References:

[1]姚建忠,许崇波,刘齐贵,等.表达人白细胞介素-2重组耻垢分枝杆菌疫苗株的建立[J].第三军医大学学报,2005,27(07):600.
[2]李俊明,朱道银,王娜,等.icl mRNA特异性10-23DRz在小鼠体内抗结核分枝杆菌感染的实验研究[J].第三军医大学学报,2010,32(06):541.
 Li Junming,Zhu Daoyin,Wang Na,et al.10-23 deoxyribozyme targeting icl mRNA inhibits Mycobacterium tuberculosis infection in mice[J].J Third Mil Med Univ,2010,32(18):541.
[3]张勇,靳风烁,李黔生,等.分枝杆菌Ag85B多克隆抗体的研制[J].第三军医大学学报,2004,26(11):0.[doi:10.16016/j.1000-5404.2004.11.012 ]
 ZHANG Yong,JIN Feng shuo,LI Qian sheng,et al.[J].J Third Mil Med Univ,2004,26(18):0.[doi:10.16016/j.1000-5404.2004.11.012 ]

更新日期/Last Update: 2008-07-16